Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: GlobeNewswire
David Moatazedi has Proven and Extensive Track Record of Building Fast Growing Aesthetics Market Led Entire U.S. Aesthetics Portfolio Including Botox® Cosmetic IRVINE, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a lifestyle aesthetics company, announced that its board of directors has named David Moatazedi as President and Chief Executive Officer. Mr. Moatazedi joins Evolus from Allergan where he most recently served as Senior Vice President of U.S. Medical Aesthetics, leading the entire aesthetic portfolio of brands including Botox® Cosmetic, JUVEDERM® Collection, CoolSculpting®, KYBELLA®, SkinMedica®, Latisse®, Natrelle® and Alloderm®. David joins Evolus as of May 6, 2018 and will succeed Murthy Simhambhatla, who has decided to pursue other options. Mr. Moatazedi has nearly twenty years of commercial and executive experience building multiple market leading brands. David also led several acquisitions for Allergan, i
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 [Seeking Alpha]Seeking Alpha
- AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements [Yahoo! Finance]Yahoo! Finance
- AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine [Yahoo! Finance]Yahoo! Finance
- Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 3/7/24 - Miss
EOLS
Sec Filings
- 3/21/24 - Form 4
- 3/21/24 - Form 4
- 3/21/24 - Form 4
- EOLS's page on the SEC website